Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic use in France and Italy: an electronic medical records databases study

24/09/2015
22/02/2024
EU PAS number:
EUPAS11081
Study
Finalised
Subscribe
Download as PDF
Study identification

EU PAS number

EUPAS11081

Study ID

33991

Official title and acronym

Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic use in France and Italy: an electronic medical records databases study

DARWIN EU® study

No

Study countries

France
Italy

Study description

The aim of this drug utilization study is to characteriseprescribing practices of TCC-containing medicinal productsduring typical clinical use in representative groups ofprescribers and assess main reasons for prescription.The study objectives are:• To describe the demographic and clinicalcharacteristics of the treated patients (i.e. age andgender, co-medications, pregnancy, contraceptive use,lactation)• To describe for which indication TCC is prescribed inroutine clinical practice (overall and by age/gender)• To describe the average duration of treatment episodesand the daily doses prescribed according to the routeof administration• To compare patients characteristics pre- and postimplementationof RMMs

Study status

Finalised
Research institutions and networks

Institutions

Multiple centres: 100 centres are involved in the study

Contact details

Intissar Bourahla

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Marketing Authorization Holder
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 1 (imposed as condition of marketing authorisation)